The FDA's Pediatric Advisory Committee will investigate the neurological and behavioral side effects of Roche Holding's influenza drug Tamiflu on children who have taken the treatment. The panel is scheduled to meet on Nov. 27 to discuss Tamiflu's safety in the age group, two years after the drug was linked to the deaths of at least 12 Japanese children.

Full Story:

Related Summaries